Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A. Chanan-Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin HuangYuqiu Jiang, Sindy T. Kim, Sophia Randolph, Selina Chen-Kiang

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint Dive into the research topics of 'Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences